$127 Million is the total value of Sio Capital Management, LLC's 30 reported holdings in Q4 2014. The portfolio turnover from Q3 2014 to Q4 2014 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| QTNT | New | QUOTIENT LTD | $21,831,000 | – | 1,212,850 | +100.0% | 17.15% | – |
| SNY | New | SANOFI-ADRadr | $11,836,000 | – | 259,500 | +100.0% | 9.30% | – |
| GSK | New | GLAXOSMITHKLINE PLC-SPON ADRadr | $8,991,000 | – | 210,371 | +100.0% | 7.06% | – |
| F113PS | New | COVIDIEN PLC | $8,745,000 | – | 85,500 | +100.0% | 6.87% | – |
| ADMP | New | ADAMIS PHARMACEUTICALS CORP | $7,210,000 | – | 1,168,566 | +100.0% | 5.66% | – |
| PETX | New | ARATANA THERAPEUTICS INC | $5,799,000 | – | 325,420 | +100.0% | 4.56% | – |
| AFAM | New | ALMOST FAMILY INC | $5,669,000 | – | 195,807 | +100.0% | 4.45% | – |
| CFN | New | CAREFUSION CORP | $5,317,000 | – | 89,600 | +100.0% | 4.18% | – |
| CAH | New | CARDINAL HEALTH INC | $5,013,000 | – | 62,100 | +100.0% | 3.94% | – |
| AGRX | New | AGILE THERAPEUTICS INC | $4,604,000 | – | 749,887 | +100.0% | 3.62% | – |
| BDSI | New | BIODELIVERY SCIENCES INTL | $4,472,000 | – | 372,043 | +100.0% | 3.51% | – |
| JNJ | New | JOHNSON & JOHNSON | $4,183,000 | – | 40,000 | +100.0% | 3.29% | – |
| PFNX | New | PFENEX INC | $4,026,000 | – | 560,765 | +100.0% | 3.16% | – |
| BIOS | New | BIOSCRIP INC | $3,877,000 | – | 554,621 | +100.0% | 3.05% | – |
| ADMA | New | ADMA BIOLOGICS INC | $2,747,000 | – | 245,930 | +100.0% | 2.16% | – |
| OFIX | New | ORTHOFIX INTERNATIONAL NV | $2,345,000 | – | 78,007 | +100.0% | 1.84% | – |
| FWP | New | FORWARD PHARMA A/S-ADRadr | $2,269,000 | – | 108,915 | +100.0% | 1.78% | – |
| CNMD | New | CONMED CORP | $2,252,000 | – | 50,100 | +100.0% | 1.77% | – |
| ESPR | New | ESPERION THERAPEUTICS INC | $2,168,000 | – | 53,600 | +100.0% | 1.70% | – |
| NSPH | New | NANOSPHERE INC | $2,112,000 | – | 5,386,213 | +100.0% | 1.66% | – |
| SRNE | New | SORRENTO THERAPEUTICS INC | $1,860,000 | – | 184,720 | +100.0% | 1.46% | – |
| SCYX | New | SCYNEXIS INC | $1,722,000 | – | 172,581 | +100.0% | 1.35% | – |
| TGTX | New | TG THERAPEUTICS INC | $1,627,000 | – | 102,700 | +100.0% | 1.28% | – |
| MMSI | New | MERIT MEDICAL SYSTEMS INC | $1,613,000 | – | 93,072 | +100.0% | 1.27% | – |
| CBAY | New | CYMABAY THERAPEUTICS INC | $1,198,000 | – | 121,900 | +100.0% | 0.94% | – |
| CTIC | New | CTI BIOPHARMA CORP | $1,192,000 | – | 505,000 | +100.0% | 0.94% | – |
| New | REWALK ROBOTICS LTD | $1,127,000 | – | 59,707 | +100.0% | 0.88% | – | |
| CLTX | New | CELSUS THERAPEUTICS-SPON ADRadr | $881,000 | – | 183,505 | +100.0% | 0.69% | – |
| HART | New | HARVARD APPARATUS REGENERATI | $430,000 | – | 135,262 | +100.0% | 0.34% | – |
| ADXS | New | ADVAXIS INCwarrant | $161,000 | – | 39,000 | +100.0% | 0.13% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-02-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VIKING THERAPEUTICS INC | 24 | Q3 2023 | 3.4% |
| UNITED THERAPEUTICS ORD | 23 | Q3 2023 | 8.3% |
| CARDINAL HEALTH ORD | 20 | Q2 2022 | 7.2% |
| SANOFI SA | 19 | Q3 2022 | 9.8% |
| MEDTRONIC PLC | 18 | Q3 2023 | 5.2% |
| CATALYST BIOSCIENCES INC | 18 | Q3 2021 | 17.8% |
| PFENEX ORD | 18 | Q4 2019 | 5.9% |
| AEGLEA BIOTHERAPEUTICS INC | 18 | Q1 2023 | 1.1% |
| HCA HEALTHCARE INC | 17 | Q2 2022 | 5.5% |
| MCKESSON ORD | 17 | Q1 2022 | 6.0% |
View Sio Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Modular Medical, Inc. | February 13, 2023 | 1,091,479 | 10.0% |
| Cellectar Biosciences, Inc. | February 10, 2022 | ? | ? |
| CURIS INC | February 10, 2022 | 3,866,645 | 4.2% |
| Salarius Pharmaceuticals, Inc. | February 10, 2022 | 1,354,291 | 3.0% |
| Larimar Therapeutics, Inc. | February 16, 2021 | 188,661 | 1.2% |
| ACHIEVE LIFE SCIENCES, INC. | February 14, 2020 | ? | ? |
| Bionano Genomics, Inc | February 14, 2020 | 1,210,821 | 4.6% |
| Brickell Biotech, Inc. | February 14, 2020 | ? | ? |
| Trillium Therapeutics Inc. | February 14, 2020 | 2,751,186 | 9.8% |
| ZAFGEN, INC. | February 14, 2020 | 2,283,164 | 6.1% |
View Sio Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| SC 13G | 2023-02-13 |
| 13F-HR | 2022-11-14 |
View Sio Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.